Table 2.

Small molecule inhibitor of IGF2BPs

IGF2BPs	Inhibitors	Cancer types	Target site	Effect	Ref
IGF2BP1	BTYNB	Melanoma, Ovarian cancer	Unknown	Disrupting the interaction between	117, 118
				IGF2BP1 and target mRNAs
	7773	Lung cancer	A hydrophobic surface at the	Reducing the level of mRNA targets	119
			boundary of KH3 and KH4 domain
	Cucurbitacin B	HCC	The Cys253 site in the KH1-2 domain	A pharmacological allosteric effect to inhibit	73
				recognition of target mRNAs
	C646	Intrahepatic	H3K27ac in the promoter of IGF2BP1	Decreasing the IGF2BP1 mRNA and protein	45
		cholangiocarcinoma		expression
IGF2BP2	Ten compounds,	CRC, Liver cancer	RRM1 and KH3-4 (Compounds	Reducing tumor cell proliferation	120
	belonging to the		from benzamidobenzoic acid class),
	benzamidobenzoic acid class		Unknown (Compounds from
	and ureidothiophene class		ureidothiophene class)
	JX5	Leukemia	KH3-4 domain	Suppressing the cancer progression without	121
				influencing the IGF2BP2 mRNA levels
	CWI1-2	Leukemia	The hydrophobic pocket within	Decreasing downstream RNA and protein levels of	122
			the KH4 domain	IGF2BP2 to exert anti-tumor efficacy
IGF2BP3	JQ1 and I-BET151	Leukemia,	Unknown	Decreasing levels of IGF2BP3 and its mRNA	27, 123
		Ewing Sarcoma		targets to hinder tumor growth
	Berberine	CRC	Unknown	Down-regulating IGF2BP3 at the protein level to	105, 124
				inhibit CRC growth
	Isoliquiritigenin	Non-small cell lung cancer	Unknown	Reducing IGF2BP3 at the mRNA and protein level	125
				to inhibit lung cancer progression
	RIG	Lung adenocarcinoma	Unknown	Reducing IGF2BP3 expression and tumor growth	57